Key Takeaways
- ARK Invest’s Cathie Wood limited her stock purchases to just three companies last week: Figma, Arcturus Therapeutics, and 10x Genomics
- The firm acquired 337,381 Figma shares totaling more than $8.1 million on March 20
- Circle Internet Group, a cryptocurrency-related holding, saw ARK divest 45,998 shares worth approximately $5.9 million from ARKK and ARKW
- Despite reporting 40% revenue expansion in recent earnings, Figma shares have plummeted 83% from their 2025 peak
- Additional sales included positions in Teradyne, Bullish, Guardant Health, and Butterfly Network
Cathie Wood, who leads ARK Invest as founder and chief executive, demonstrated unusually restrained buying activity last week, acquiring positions in only three companies while markets experienced their fourth consecutive week of losses. All three primary equity benchmarks registered declines throughout this timeframe.
This limited purchasing activity marked a departure from Wood’s typical pattern of more aggressive accumulation during market downturns, catching the attention of market watchers.
The trio of stocks receiving fresh capital included Figma, Arcturus Therapeutics, and 10x Genomics. Simultaneously, the investment firm reduced exposure to multiple holdings, most notably Circle Internet Group, which operates in the cryptocurrency sector.
Figma operates a cloud-native design platform serving teams building websites, applications, and other digital experiences. On March 20, ARK accumulated 337,381 shares distributed between its ARKK and ARKW exchange-traded funds, representing an investment of $8,171,367.
Shares have tumbled 83% from last summer’s highs, following a remarkable surge that pushed the stock more than four times above its $33 initial public offering price. Yet the company’s fundamentals remain robust, with its latest quarterly results showing 40% top-line expansion, accelerating from 38% in the prior period.
The platform’s net dollar-retention metric reached 136%, indicating that existing clients increased their spending by 36% year-over-year. This represents the best performance on this indicator in 24 months.
Wall Street forecasts anticipate revenue growth moderating to 30% in the current year and 20% in the following year. The company’s lack of consistent profitability has been a headwind for investor sentiment.
Cryptocurrency Exposure Trimmed With Circle Internet Sale
In the digital asset space, ARK liquidated 45,998 shares of Circle Internet Group distributed across ARKK and ARKW, generating proceeds of $5,902,923. The firm had been systematically reducing this position throughout the week.
Circle Internet operates in the cryptocurrency infrastructure sector and plays a significant role in the USD Coin stablecoin market.
Additional divestitures included 19,206 Teradyne shares for $5,807,894, 103,379 Bullish shares generating $4,093,808, and 9,621 Guardant Health shares for $857,038. The firm also exited 182,353 Butterfly Network shares, receiving $723,941.
Biotechnology Focus: Arcturus and 10x Genomics Additions
Arcturus Therapeutics leverages messenger RNA platforms to create therapies targeting uncommon respiratory and hepatic conditions. ARK added to this position on three separate days during the trading week, culminating in a Friday purchase of 22,773 shares valued at $153,034 through the ARKG ETF.
The company has experienced declining revenues for three consecutive years, with projections suggesting further contraction through 2026. Nevertheless, management recently announced an extension of its financial runway through at least mid-2028.
10x Genomics manufactures scientific instruments for life sciences research, notably its Chromium system designed for single-cell genomic sequencing. ARK purchased 192,658 shares distributed between ARKK and ARKG last week, investing $3,541,054.
The stock debuted at $38 per share and currently trades near half that valuation. The company remains unprofitable, and its own 2026 revenue outlook suggests a contraction when adjusting for licensing revenues from prior-year patent settlements.